According to the World Health Organization, cardiovascular disease (CVD) remains the
leading cause of death worldwide, accounting for approximately 18 million deaths per year …

Background and aims Many patients treated with statins are considered statin-resistant
because they fail to achieve adequate reduction of low density lipoprotein cholesterol (LDL …

Background Statin use could benefit patients with non-alcoholic fatty liver disease (NAFLD),
but the evidence is segmented and inconclusive. This multidimensional study …

Statins reduce cardiovascular mortality and morbidity as well as cardiovascular events in
patients with a very high risk of cardiovascular disease (CVD) and also in subjects with high …

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of
abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence …

Purpose of review The purpose of this study is to analyze the current evidence regarding the
use of statins in patients with chronic liver disease and cirrhosis. Recent findings Chronic …

Abstract Background Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most common
causes of chronic liver disease worldwide. There is no universally accepted effective …

Background: Nonalcoholic fatty liver disease (NAFLD) is a common complication in patients
with metabolic syndrome. The role of statin therapy specifically for the treatment of NAFLD …

The elderly population is increasing worldwide, with subjects> 65 years of age constituting
the fastest-growing age group. Furthermore, the elderly face the greatest risk and burden of …

Background The prevalence of liver fibrosis among diabetic patients is increasing rapidly.
Our study aims at exploring the relationship between antidepressant use and liver fibrosis in …